Virtual Support, Real Impact: Effectiveness of Tele-nursing in Alleviating Chemotherapy Symptoms Among Cancer Patients

Not Applicable

Completed

• Conditions: Cancer; Chemotherapy Effect; Quality of Life (QOL)

• Registration Number: NCT06702982
• Lead Sponsor: Helwan University

Brief Summary

This quasi-experimental study evaluated a tele-nursing educational program's impact on improving the quality of life and managing chemotherapy-related symptoms in 74 adult cancer patients at Mansoura University Hospital in Egypt. Delivered via Telegram, the program involved weekly educational sessions, aiming to enhance symptom management and quality of life.

Detailed Description

The study aimed to assess the effectiveness of a tele-nursing educational program in managing chemotherapy-related and cancer-related symptoms and improving the quality of life among adult cancer patients. Conducted at the Oncology Center at Mansoura University Hospital in Egypt, the study recruited 74 participants who completed structured interviews detailing their demographics, medical history, symptom severity (using the MDASI-A tool), and quality of life (using the QOL-ACD tool). The intervention, delivered via a Telegram group, included weekly educational sessions focused on managing chemotherapy symptoms. The sessions featured educational content and feedback, with outcomes measured through changes in symptom severity and quality of life scores before and after the intervention. This approach highlighted the program's potential to enhance patients' overall well-being and symptom management.

Study Timeline

• Study Start: 2024-01-01
• Primary Completion: 2024-04-30
• Study Completion: 2024-08-30
• Status Verified: 2024-11
• Study First Submitted: 2024-11-20
• Study First Submitted QC: 2024-11-22
• Last Update Submitted: 2024-11-22
• Study First Posted: 2024-11-25
• Last Update Posted: 2024-11-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• • Diagnosed with cancer and receiving treatment at an outpatient chemotherapy center

  • Age from 20 less than 60 years.
  • Accept to participate in the study.
  • Had smart phones linked with internet
  • Educated and able to use Zoom and Telegram applications

Exclusion Criteria

• • Having active, serious physical disease

  • Patients with mental disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
cancer-related and treatment-related symptoms	3 months	The M.D. Anderson Symptom Inventory Arabic Version (MDASI-A), adapted from Nejmi et al. (2010), was utilized to assess the severity of cancer-related and treatment-related symptoms in a manner accessible to Arabic-speaking patients. Designed in straightforward Arabic, the tool evaluates both the intensity of 13 core symptoms commonly experienced by cancer patients and their interference with daily functioning. This makes the MDASI-A comprehensive while remaining brief enough to avoid imposing a burden on respondents.; The MDASI-A employs a 0-2 numerical scale (Never = 0, Sometimes = 1, Always = 2), ensuring its usability even among less-educated individuals. It is also adaptable for telephone, computer, and other electronic methods of administration. Scores were converted to percentages to classify symptom intensity into three categories: low (\<50%), average (50% to \<75%), and high (≥75%) based on the method proposed by Daisuke and Makoto (2022).

Secondary Outcome Measures

Name	Time	Method
Quality of life for Cancer Patients	3 months	The Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD), adopted from Kurihara et al. (1999), was employed to assess the quality of life (QOL) among patients undergoing anticancer treatment. This questionnaire comprises 22 items distributed across five domains: six items for daily activities, five for physical condition, five for mental and psychological status, five for social activities, and one for general QOL (evaluated via a face scale). Each item was rated on a 5-point scale, with scores ranging from 1 (lowest QOL) to 5 (highest QOL), yielding a total score between 22 and 110; higher scores indicate better QOL.; Patients' responses were classified into three categories based on their scores: good (≤75%), average (50%-\<75%), and low (\>50%), according to the scoring framework by Saad and Elsayed (2021). Negative statements were reverse scored to align with the Likert scale format, ensuring consistency in the evaluation.

Trial Locations

Locations (1)

Mansura university; 🇪🇬 Mansura, Dakhalia, Egypt